Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 3108  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page
SPECIAL ARTICLE
Year : 2022  |  Volume : 67  |  Issue : 3  |  Page : 314

Evidence-based guidelines for SARS-COV-2 vaccination of patients of skin allergic diseases and patients on immuno-therapeutics


1 Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India
2 Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
3 Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, Navi Mumbai, Maharashtra, India
4 Skin Care Centre, Rajajinagar, Bengaluru, Karnataka, India
5 Department of Dermatology, Skin Diseases Center, Nashik, Madhya Pradesh, India
6 Department of Dermatology, The Medicity, Medanta Hospital, Gurugram, Haryana, India
7 Max Super Speciality Hospital, Patparganj, New Delhi, India
8 Department of Dermatology, College of Medicine, Sagore Dutta Hospital, Kolkata, West Bengal, India
9 Department of Dermatology, BJ Medical College, Ahmedabad, Gujarat, India
10 Department of Dermatology, Institute of Child Health, Kolkata, West Bengal, India

Correspondence Address:
Sandipan Dhar
Department of Dermatology, Institute of Child Health, Kolkata, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijd.ijd_440_21

Rights and Permissions

There is a dearth of data regarding the safety and timing of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination of patients on immunosuppressive or immunomodulatory therapies. However, data from other vaccine trials may be extrapolated to get an idea regarding the recommendation of SARS-COV-2 vaccines. All the novel SARS-COV-2 vaccines are non-live, thus ensuring the safety of the vaccines. However, the vaccines may not be able to generate an equipotent immunogenic response in patients receiving immunotherapeutics, in comparison to those who are not. We have attempted to put forward certain statements, with respect to SARS-COV-2 vaccination of patients who are on treatment for different dermatological conditions. However, the risk-benefit ratio must be discussed between the patient and the physician, and the final call should be individualized.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed144    
    Printed2    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal